

# CITATION REPORT

List of articles citing

Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing

DOI: 10.1016/j.lungcan.2014.11.018  
Lung Cancer, 2015, 87, 122-9.

**Source:** <https://exaly.com/paper-pdf/62783325/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
51	Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , <b>2015</b> , 6, 35-42	2.9	1
50	Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 375-85	3.5	
49	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. <i>Cancer Gene Therapy</i> , <b>2015</b> , 22, 417-30	5.4	96
48	ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making. <i>Lung Cancer</i> , <b>2015</b> , 90, 465-71	5.9	33
47	Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer. <i>Journal of Personalized Medicine</i> , <b>2016</b> , 6,	3.6	6
46	Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET. <i>Journal of Pathology: Clinical Research</i> , <b>2016</b> , 2, 210-222	5.3	11
45	c-Met expression and MET amplification in malignant pleural mesothelioma. <i>Annals of Diagnostic Pathology</i> , <b>2016</b> , 23, 1-7	2.2	9
44	Testing for ROS1 in non-small cell lung cancer: a review with recommendations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2016</b> , 469, 489-503	5.1	146
43	Molecular Pathology: A Requirement for Precision Medicine in Cancer. <i>Oncology Research and Treatment</i> , <b>2016</b> , 39, 804-810	2.8	16
42	Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement. <i>BMC Cancer</i> , <b>2016</b> , 16, 599	4.8	17
41	Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer. <i>BMC Cancer</i> , <b>2016</b> , 16, 603	4.8	26
40	MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3048-56	12.9	226
39	Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, 30-8.e1	4.9	18
38	New Insight into the Synthesis of Aromatic Azo Compounds Assisted by Surface Plasmon Resonance. <i>Plasmonics</i> , <b>2017</b> , 12, 611-620	2.4	5
37	Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 55, 83-95	14.4	48
36	[Crizotinib for ROS1-rearranged non-small cell lung cancer patients]. <i>Bulletin Du Cancer</i> , <b>2017</b> , 104, 303-310	3.1	1
35	Preferential Localization of MET Expression at the Invasion Front and in Spreading Cells Through Air Spaces in Non-Small Cell Lung Carcinomas. <i>American Journal of Surgical Pathology</i> , <b>2017</b> , 41, 414-422	6.7	5

34	Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy. <i>Targeted Oncology</i> , <b>2017</b> , 12, 487-494	5	23
33	ROS1 [corrected]. <i>Journal of Clinical Pathology</i> , <b>2017</b> , 70, 1001-1009	3.9	13
32	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmeier and Alberto Cavazza. <i>European Respiratory Review</i> , <b>2017</b> , 26,	9.8	49
31	Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives. <i>Lung Cancer: Targets and Therapy</i> , <b>2017</b> , 8, 45-55	2.9	22
30	Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm.. <i>JCO Precision Oncology</i> , <b>2017</b> , 1, 1-9	3.6	5
29	Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2017</b> , 6, 570-587	4.4	26
28	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 323-358	8.9	241
27	Big data and precision medicine: challenges and strategies with healthcare data. <i>International Journal of Data Science and Analytics</i> , <b>2018</b> , 6, 241-249	2	10
26	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2018</b> , 142, 331-346	5	371
25	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , <b>2018</b> , 20, 129-159	5.1	165
24	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2018</b> , 142, 408-419	5	52
23	Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. <i>Modern Pathology</i> , <b>2018</b> , 31, 307-312	9.8	17
22	Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 10058-10063	11.5	11
21	Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer. <i>International Journal of Biological Markers</i> , <b>2018</b> , 1724600818772194	2.8	6
20	Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options. <i>Lung Cancer</i> , <b>2019</b> , 138, 43-51	5.9	10
19	Crizotinib in -Deregulated or -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 7312-7319	12.9	80
18	DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer. <i>Modern Pathology</i> , <b>2019</b> , 32, 855-865	9.8	18
17	Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1204-1212	8.9	20

16	Recommendations for Ancillary Testing. <b>2019</b> , 125-142		
15	The Papanicolaou Society of Cytopathology System for Reporting Respiratory Cytology. <b>2019</b> ,		6
14	Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring Intron 14 Mutation: A Case Report. <i>OncoTargets and Therapy</i> , <b>2021</b> , 14, 3949-3958	4.4	
13	The genomic and transcriptional landscape of primary central nervous system lymphoma.		0
12	Adequate tissue for adequate diagnosis: what do we really need?. 119-135		1
11	Clinicopathological characteristics of and rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. <i>Oncotarget</i> , <b>2017</b> , 8, 53336-53351	3.3	30
10	Has MET met its match?. <i>Annals of Translational Medicine</i> , <b>2016</b> , 4, 97	3.2	4
9	Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , <b>2015</b> , 4, 300-9	4.4	26
8	Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma. <i>Cancer Research and Treatment</i> , <b>2020</b> , 52, 481-491	5.2	10
7	Fish for MET Amplifications. <b>2016</b> , 4-8-4-11		
6	Clinical characteristics of patients with gene rearrangement in non-small cell lung cancer: a meta-analysis.. <i>Translational Cancer Research</i> , <b>2020</b> , 9, 4383-4392	0.3	1
5	High Expression of NT5DC2 Is a Negative Prognostic Marker in Pulmonary Adenocarcinoma.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	0
4	The genomic and transcriptional landscape of primary central nervous system lymphoma.. <i>Nature Communications</i> , <b>2022</b> , 13, 2558	17.4	4
3	Evaluation Criteria for Chromosome Instability Detection by FISH to Predict Malignant Progression in Premalignant Glottic Laryngeal Lesions. <i>Cancers</i> , <b>2022</b> , 14, 3260	6.6	
2	DNA methylation-based classification of sinonasal tumors. <b>2022</b> , 13,		1
1	State of the Art of Pathologic and Molecular Testing. <b>2023</b> ,		0